Pharmaceutical Companies in Oman
A comprehensive guide to the pharmaceutical industry in Oman — a smaller GCC market that is strategically important. Covering major pharma companies, MOH DGPA regulatory framework, Vision 2040 healthcare modernisation, market data ($0.7B, 6.9% growth), distribution channels, and strategic opportunities.
Last updated: February 2026 · Sources: MOH DGPA, BioNixus MEA, company filings
Cite this guide
BioNixus. "Pharmaceutical Companies in Oman: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-oman.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$0.7B
Pharmaceutical market value
6.9%
Year-over-year growth
4.6M
Population
$152
Pharma spending per capita
Oman Pharmaceutical Market Overview
Oman's pharmaceutical market is a smaller GCC market but strategically important, valued at approximately US$0.7 billion, growing at 6.9% year-over-year. With a population of 4.6 million and per-capita pharmaceutical spending of $152, Oman is undergoing healthcare modernisation under Vision 2040, with approximately 90% of pharmaceuticals imported and local manufacturing expanding with government incentives.
Vision 2040 targets healthcare sector development, digital health adoption, and support for local pharmaceutical production. Chronic disease burden, growing insurance coverage, and medical tourism from the region are key demand drivers. The market is regulated by the Ministry of Health Directorate General of Pharmaceutical Affairs (MOH DGPA), with pricing moving toward the GCC unified pricing framework (in progress).
For a broader regional comparison, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Oman
The following table lists the major pharmaceutical companies operating in Oman — including local manufacturers, multinational corporation offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| Oman Pharmaceutical Products Co. (omanpharma) | Oman |
| National Pharmaceutical Industries (NPI) | Oman |
| Gulf Pharma | Oman |
| Pfizer | USA |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK (GlaxoSmithKline) | UK |
| MSD (Merck & Co.) | USA |
| Novo Nordisk | Denmark |
| AbbVie | USA |
| Boehringer Ingelheim | Germany |
| Julphar | UAE |
| Hikma Pharmaceuticals | Jordan / UK |
| Tabuk Pharmaceutical | Saudi Arabia |
| Muscat Pharmacy | Oman |
| Oman Medical Trading | Oman |
| National Distribution Company | Oman |
List of Pharmaceutical Companies in Oman by Category
Oman pharmaceutical companies span local manufacturers (omanpharma, NPI, Gulf Pharma), multinational offices, regional players with strong Oman presence, and major distributors.
Local Manufacturers
Oman has a small but growing local manufacturing base. Oman Pharmaceutical Products Co. (omanpharma) is the leading local manufacturer; National Pharmaceutical Industries (NPI) is Muscat-based generics; Gulf Pharma produces oral solids and liquids. Vision 2040 incentives support expansion of domestic production.
- ✓ Oman Pharmaceutical Products Co. (omanpharma)
- ✓ National Pharmaceutical Industries (NPI)
- ✓ Gulf Pharma
Multinational Pharma Offices
Major global pharmaceutical companies maintain presence in Oman. MNCs dominate the innovator drug segment and drive adoption of advanced therapies. Key players include Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, MSD, Novo Nordisk, AbbVie, and Boehringer Ingelheim.
- ✓ Pfizer
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK (GlaxoSmithKline)
- ✓ MSD (Merck & Co.)
- ✓ Novo Nordisk
- ✓ AbbVie
- ✓ Boehringer Ingelheim
Regional Pharma Companies
Regional pharmaceutical companies play important roles in Oman: Julphar with strong Oman exports, Hikma Pharmaceuticals, and Tabuk Pharmaceutical. They benefit from GCC regulatory harmonisation.
- ✓ Julphar
- ✓ Hikma Pharmaceuticals
- ✓ Tabuk Pharmaceutical
Distributors
Key distributors in Oman include Muscat Pharmacy, Oman Medical Trading, and National Distribution Company, serving both government and private channels as insurance expansion grows the private sector.
- ✓ Muscat Pharmacy
- ✓ Oman Medical Trading
- ✓ National Distribution Company
Pharma Companies in Oman: MOH DGPA Regulatory Landscape
The Ministry of Health Directorate General of Pharmaceutical Affairs (MOH DGPA) oversees pharmaceutical registration, quality control, and market access in Oman.
Regulatory Authority
The Ministry of Health Directorate General of Pharmaceutical Affairs (MOH DGPA) oversees pharmaceutical registration, quality control, pharmacovigilance, and import licensing. Oman is moving toward GCC unified pricing framework (in progress).
Registration Timeline
10–18 months
Renewal Period
5 years
Pricing Model
GCC unified pricing framework (in progress)
Key Registration Requirements
- ✓Dossier submission via MOH DGPA (CTD format where applicable)
- ✓GMP certificates from recognised authorities
- ✓Stability data for Zone IVB climate conditions
- ✓Arabic labelling mandatory on all products
- ✓Clinical trial data and bioequivalence studies (generics)
- ✓Certificate of Pharmaceutical Product (CPP)
- Local authorised representative mandatory
Vision 2040 & Local Manufacturing Incentives
Under Vision 2040, Oman supports healthcare modernisation and local pharmaceutical manufacturing incentives. Approximately 90% of the market is import-dependent; government programmes aim to expand domestic production. For complete GCC registration details, see our GCC Pharmaceutical Market Access Guide.
Drug Distribution Channels in Oman
Oman's pharmaceutical distribution is dominated by government healthcare (free for Omani nationals), with the private sector growing as insurance expands.
Government Channel (Dominant)
Government healthcare is dominant, with free care for Omani nationals. MOH hospitals, Royal Hospital, and Sultan Qaboos University Hospital form the core of public-sector procurement and dispensing.
- ► MOH hospitals and primary care
- ► Royal Hospital
- ► Sultan Qaboos University Hospital
- ► Tender-based procurement
Private Sector (Growing)
The private sector is growing with insurance expansion. Distributors such as Muscat Pharmacy, Oman Medical Trading, and National Distribution Company serve both channels.
- ► Growing insurance coverage driving private utilisation
- ► Private hospitals and clinics
- ► Retail pharmacy and OTC
Oman Pharmaceutical Market Growth Drivers
Vision 2040 and structural factors are driving growth in Oman's pharmaceutical sector.
Vision 2040 Healthcare Modernisation
Oman's national plan prioritises healthcare modernisation, hospital infrastructure, digital health adoption, and support for local pharmaceutical manufacturing.
Local Manufacturing Incentives
Government incentives aim to expand domestic production, reducing import dependency from ~90% and creating opportunities for local and regional manufacturers.
Growing Insurance Coverage
Expansion of health insurance is driving private-sector pharmaceutical utilisation and creating reimbursement dynamics alongside the dominant government channel.
Chronic Disease Burden
Rising prevalence of diabetes, cardiovascular disease, and other chronic conditions drives sustained demand for metabolic and specialty therapies.
Medical Tourism from Region
Oman attracts medical tourism from the region, supporting demand for quality healthcare and pharmaceutical services.
Digital Health Adoption
Vision 2040 and post-pandemic trends are accelerating digital health adoption, creating new channels and data-driven care.
How BioNixus Supports Pharma Companies in Oman
BioNixus is a leading healthcare market research company with expertise in the Oman and GCC pharmaceutical markets. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Quantitative and qualitative research with Omani physicians across MOH, Royal Hospital, SQUH, and private sector. Arabic-English bilingual capabilities.
Market Access & MOH DGPA Strategy
MOH DGPA formulary strategy, GCC pricing context, reimbursement landscape, and payer research to optimise commercial success in Oman.
Competitive Intelligence
Monitoring of competitor launches, tender outcomes, formulary changes, and market share across therapeutic areas in Oman and the GCC.
Market Entry Strategy
Market assessment including regulatory pathway analysis, local partner identification, KOL engagement, and go-to-market planning for Oman.
Frequently Asked Questions
How many pharmaceutical companies operate in Oman?
Oman has approximately 18 pharmaceutical companies including local manufacturers (omanpharma, NPI, Gulf Pharma), multinational offices (Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, MSD, Novo Nordisk, AbbVie, Boehringer Ingelheim), regional players (Julphar, Hikma, Tabuk), and distributors (Muscat Pharmacy, Oman Medical Trading, National Distribution Company). The market is valued at $0.7 billion and is growing at 6.9% under Vision 2040 healthcare modernisation.
What is the size of Oman's pharmaceutical market?
Oman's pharmaceutical market is valued at approximately US$0.7 billion, with 6.9% year-over-year growth. The population is about 4.6 million with pharma spending per capita of $152. It is a smaller GCC market but strategically important, with ~90% of pharmaceuticals imported and local manufacturing expanding with government incentives.
How do you register a pharmaceutical product with MOH DGPA in Oman?
Drug registration in Oman is overseen by the Ministry of Health Directorate General of Pharmaceutical Affairs (MOH DGPA). The registration process typically takes 10–18 months and requires a 5-year renewal. Submissions follow GCC harmonisation where applicable; companies need a local authorised representative, GMP certificates, stability data, and Arabic labelling.
How does Vision 2040 affect Oman's pharmaceutical sector?
Vision 2040 drives healthcare modernisation in Oman, including investment in hospital infrastructure, digital health adoption, and incentives for local pharmaceutical manufacturing. Government support for domestic production and growing insurance coverage are expanding both public and private pharmaceutical utilisation.
Is local pharmaceutical manufacturing required in Oman?
Local manufacturing is not legally required but is encouraged through government incentives. Approximately 90% of pharmaceuticals are imported; Oman has a small but growing local base (omanpharma, NPI, Gulf Pharma) with Vision 2040 supporting expansion of domestic production.
Do I need a local partner to sell pharmaceuticals in Oman?
Yes, foreign pharmaceutical companies typically need a local authorised representative to handle MOH DGPA regulatory submissions, in-country logistics, and pharmacovigilance. This is standard for market access in Oman and the wider GCC.
Data Sources & Methodology
This guide aggregates publicly available information from:
- BioNixus Middle East & Africa Pharmaceutical Market Report
- MOH DGPA — Pharmaceutical regulatory and licensing information
- Company filings and public announcements
- BioNixus proprietary research from physician and market surveys in Oman and the GCC (2024–2025)
For customised market intelligence on Oman, contact our team.
Need Market Intelligence on Oman?
BioNixus delivers custom pharmaceutical market research across Oman and the GCC — physician surveys, competitive intelligence, market access strategy, and KOL mapping.